{"brief_title": "A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder", "brief_summary": "This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.", "condition": ["Major Depressive Disorder"], "intervention_type": ["Drug"], "intervention_name": ["Antidepressant + Aripiprazole"], "description": ["Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks."], "arm_group_label": ["Antidepressant + Aripiprazole"], "other_name": ["Abilify"], "criteria": "Inclusion Criteria: - Men and women, 18 years or older - Experiencing Major Depressive Disorder with a duration of minimally 8 weeks. - Treatment history of an inadequate response to at least one and no more than four antidepressants", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Disease", "Depressive Disorder", "Depression", "Depressive Disorder, Major", "Antidepressive Agents", "Aripiprazole"], "id": "NCT00095745"}